CN Patent

CN119264116B — 一种cdk6/9双重抑制剂及其制备方法与用途

Assigned to Anhui University of Traditional Chinese Medicine AHUTCM · Expires 2025-09-23 · 1y expired

What this patent protects

本发明涉及药物化学领域，具体涉及一种CDK6/9双重抑制剂及其制备方法与应用，这种抑制剂同时具有CDK6和CDK9抑制活性，对银屑病细胞模型的异常增生和炎性因子紊乱有抑制作用，并且且具有较好的安全性和CDK家族内的选择性；这种抑制剂可用作银屑病皮炎、银屑病关节炎和其他自身免疫性疾病的治疗药物。

USPTO Abstract

本发明涉及药物化学领域，具体涉及一种CDK6/9双重抑制剂及其制备方法与应用，这种抑制剂同时具有CDK6和CDK9抑制活性，对银屑病细胞模型的异常增生和炎性因子紊乱有抑制作用，并且且具有较好的安全性和CDK家族内的选择性；这种抑制剂可用作银屑病皮炎、银屑病关节炎和其他自身免疫性疾病的治疗药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN119264116B
Jurisdiction
CN
Classification
—
Expires
2025-09-23
Drug substance claim
No
Drug product claim
No
Assignee
Anhui University of Traditional Chinese Medicine AHUTCM
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.